A5025988796- Parkinson's Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Botulinum Toxin and Related Neurological Disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurological disorders and treatments
- Ginkgo biloba and Cashew Applications
- Neuroscience and Neuropharmacology Research
- Nuclear Receptors and Signaling
- Neurotransmitter Receptor Influence on Behavior
- Nerve injury and regeneration
Michigan State University
2018-2024
Converging evidence suggests a role for microglia-mediated neuroinflammation in Parkinson's disease (PD). Animal models of PD can serve as platform to investigate the degeneration PD. However, due features previously available models, interpretations contributor or consequence neurodegeneration have remained elusive. In present study, we investigated temporal relationship model synucleinopathy following intrastriatal injection pre-formed alpha-synuclein fibrils (α-syn PFFS). Male Fischer 344...
Animal models that accurately recapitulate the accumulation of alpha-synuclein (α-syn) inclusions, progressive neurodegeneration nigrostriatal system and motor deficits can be useful tools for Parkinson's disease (PD) research. The preformed fibril (PFF) synucleinopathy model in rodents generally displays these PD-relevant features, however, magnitude predictability events is far from established. We therefore sought to optimize α-syn degeneration, understand time course both. Rats were...
Examination of early phases synucleinopathy when inclusions are present, but long before neurodegeneration occurs, is critical to both understanding disease progression and the development modifying therapies. The rat alpha-synuclein (α-syn) preformed fibril (PFF) model induces synchronized that recapitulates pathological features Parkinson's (PD) can be used study progression. In this model, phosphorylated α-syn (pSyn) inclusion-containing neurons reactive microglia (major...
Parkinson's disease (PD) pathology is characterized by alpha-synuclein (α-syn) aggregates, degeneration of dopamine neurons in the substantia nigra pars compacta (SNpc), and neuroinflammation. The presence reactive glia correlates with deposition pathological α-syn early-stage PD. Thus, understanding neuroinflammatory response microglia astrocytes to synucleinopathy may identify therapeutic targets. Here we gene expression profile SNpc during early rat pre-formed fibril (PFF) model. Rats...
Preclinical studies show a link between subthalamic nucleus (STN) deep brain stimulation (DBS) and neuroprotection of nigrostriatal dopamine (DA) neurons, potentially through brain-derived neurotrophic factor (BDNF) signaling. However, the question whether DBS STN can be disease-modifying in Parkinson's disease (PD) remains unanswered. In particular, impact on α-synuclein (α-syn) aggregation, inclusion-associated neuroinflammation, BDNF levels has yet to examined context synucleinopathy. To...
β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson's disease (PD) and are hypothesized to decrease expression both alpha-synuclein mRNA (Snca) protein (α-syn). Effects β2AR agonist clenbuterol on the levels Snca α-syn were evaluated in vivo (rats mice) rat primary cortical neurons by two independent laboratories. A modest substantia nigra was observed after single acute dose rats, however, this not maintained multiple doses. In contrast,...
Abstract Examination of early phases synucleinopathy when inclusions are present, but long before neurodegeneration occurs, is critical to both understanding disease progression and the development modifying therapies. The rat alpha-synuclein (α-syn) preformed fibril (PFF) model induces synchronized that recapitulates pathological features Parkinson’s (PD) can be used study progression. In this model, phosphorylated α-syn (pSyn) inclusion-containing neurons reactive microglia (major...